Julia Warren-Ulanch, MD
Endocrinology, Diabetes & Metabolism · Raleigh, NCNPI 1912008459
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,470 of the $30,857 with a category attached, or 63.1%. 58 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 57.9% of the total. Reporting peaked in 2021 at $10,515 and has fallen 63.4% since, to $3,845 in 2025.
Across 709 payments — averaging $43.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$18K
- Corcept Therapeutics$2K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Abbott$924
- Amgen$787
- plus $7K from 52 others
What the payments were for
- Speaking & faculty fees$19,47063%
- Travel & lodging$200%
- Food & beverage$11,32237%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$12,400
- t:slim X2 insulin pump$5,250
- Korlym$1,925
- iLet Bionic Pancreas$418
- TWIIST$202
- iLet Insulin Infusion Kit Inset$139
- iLet Insulin Infusion Kit Contact Detach$139
- Tymlos$125
How this compares
$30,857 in reported general payments places this provider in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 131 | $170,217 |
| ProliaDenosumab | 68 | $118,660 |
| JardianceEmpagliflozin | 103 | $104,770 |
| MounjaroTirzepatide | 55 | $62,282 |
| Teriparatide | 13 | $49,926 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $29,611 |
| TrulicityDulaglutide | 17 | $26,325 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $25,344 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 22 | $18,828 |
| FarxigaDapagliflozin Propanediol | 19 | $17,656 |
| JanuviaSitagliptin Phosphate | 18 | $13,199 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $12,698 |
| FiaspInsulin Aspart (Niacinamide) | 11 | $11,267 |
| Repatha SureclickEvolocumab | 14 | $8,405 |
| SynthroidLevothyroxine Sodium | 80 | $7,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $1,415 | $188,160160 claims |
| AmgenProlia | $787 | $118,66068 claims |
| Boehringer IngelheimJardiance, Trijardy Xr | $486 | $110,417115 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,009 | $93,46588 claims |
| AstraZenecaFarxiga | $541 | $17,65619 claims |
| MerckJanuvia | $159 | $13,19918 claims |
| AbbVieSynthroid, Armour Thyroid | $496 | $9,067104 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $83 | $4,173319 claims |
| PfizerLevoxyl | $126 | $1,92340 claims |
| IBSA Pharma Inc.Tirosint | $161 | $1,91312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Raleigh
- Corey BerlinRaleigh$742K
- Denis BeckerRaleigh$459K
- Elizabeth HoltRaleigh$167K
- Bhairavi SheshadriRaleigh$28K
- Glenn StallRaleigh$9K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.